Circadian Regulation of Macrophages and Osteoclasts in Rheumatoid Arthritis.
circadian rhythms
cytokine
inflammation
macrophage
osteoclasts
rheumatoid arthritis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
12
06
2023
revised:
28
07
2023
accepted:
28
07
2023
medline:
14
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) represents one of the best examples of circadian fluctuations in disease severity. Patients with RA experience stiffness, pain, and swelling in afflicted joints in the early morning, which tends to become milder toward the afternoon. This has been primarily explained by the higher blood levels of pro-inflammatory hormones and cytokines, such as melatonin, TNFα, IL-1, and IL-6, in the early morning than in the afternoon as well as insufficient levels of anti-inflammatory cortisol, which rises later in the morning. Clinical importance of the circadian regulation of RA symptoms has been demonstrated by the effectiveness of time-of-day-dependent delivery of therapeutic agents in chronotherapy. The primary inflammatory site in RA is the synovium, where increased macrophages, T cells, and synovial fibroblasts play central roles by secreting pro-inflammatory cytokines, chemokines, and enzymes to stimulate each other, additional immune cells, and osteoclasts, ultimately leading to cartilage and bone erosion. Among these central players, macrophages have been one of the prime targets for the study of the link between circadian rhythms and inflammatory activities. Gene knockout experiments of various core circadian regulators have established that disruption of any core circadian regulators results in hyper- or hypoactivation of inflammatory responses by macrophages when challenged by lipopolysaccharide and bacteria. Although these stimulations are not directly linked to RA etiology, these findings serve as a foundation for further study by providing proof of principle. On the other hand, circadian regulation of osteoclasts, downstream effectors of macrophages, remain under-explored. Nonetheless, circadian expression of the inducers of osteoclastogenesis, such as TNFα, IL-1, and IL-6, as well as the knockout phenotypes of circadian regulators in osteoclasts suggest the significance of the circadian control of osteoclast activity in the pathogenesis of RA. More detailed mechanistic understanding of the circadian regulation of macrophages and osteoclasts in the afflicted joints could add novel local therapeutic options for RA.
Identifiants
pubmed: 37569682
pii: ijms241512307
doi: 10.3390/ijms241512307
pmc: PMC10418470
pii:
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Interleukin-6
0
Cytokines
0
Interleukin-1
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM137603
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA249558
Pays : United States
Organisme : NIAMS NIH HHS
ID : R21 AR076167
Pays : United States
Références
Genome Res. 2021 Jan 12;:
pubmed: 33436377
Dev Cell. 2002 Dec;3(6):889-901
pubmed: 12479813
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9897-902
pubmed: 23716692
Crit Rev Biomed Eng. 2016;44(3):177-191
pubmed: 28605351
J Immunol Res. 2014;2014:263625
pubmed: 25295284
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12662-7
pubmed: 22778400
Immunity. 2012 Feb 24;36(2):251-61
pubmed: 22342842
Ann Rheum Dis. 1964 Mar;23:158-62
pubmed: 14130037
Z Rheumatol. 2018 Apr;77(3):249-255
pubmed: 27900440
Br J Pharmacol. 2018 Aug;175(16):3190-3199
pubmed: 29318587
J Clin Endocrinol Metab. 1995 Nov;80(11):3185-90
pubmed: 7593424
Arthritis Rheum. 2007 Feb;56(2):399-408
pubmed: 17265475
Biomed Pharmacother. 2023 Jan;157:114019
pubmed: 36423544
Int J Mol Sci. 2022 Nov 08;23(22):
pubmed: 36430199
Pharmaceutics. 2021 Nov 02;13(11):
pubmed: 34834246
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1543-1551
pubmed: 31900362
Front Immunol. 2020 Aug 04;11:1743
pubmed: 32849621
Nature. 2019 Apr;568(7753):541-545
pubmed: 30971820
Ann Rheum Dis. 1993 Mar;52(3):232-4
pubmed: 8484679
J Immunol Res. 2014;2014:282495
pubmed: 24901009
Cell. 2020 Mar 19;180(6):1044-1066
pubmed: 32164908
Front Immunol. 2017 Dec 20;8:1836
pubmed: 29326713
Nat Rev Mol Cell Biol. 2020 Feb;21(2):67-84
pubmed: 31768006
ScientificWorldJournal. 2014;2014:685854
pubmed: 25401152
Science. 2013 Sep 27;341(6153):1483-8
pubmed: 23970558
Bone. 2019 Apr;121:172-180
pubmed: 30659979
Arthritis Rheumatol. 2016 Apr;68(4):805-16
pubmed: 26554541
Ann Rheum Dis. 1994 Aug;53(8):521-4
pubmed: 7944637
Ann Phys Med. 1968 Nov;9(8):322-7
pubmed: 4881234
Inflamm Regen. 2022 Sep 2;42(1):27
pubmed: 36050796
Biomolecules. 2020 Dec 31;11(1):
pubmed: 33396412
Clin Exp Rheumatol. 2013 Jul-Aug;31(4):498-505
pubmed: 23415134
J Mol Med (Berl). 2019 Jan;97(1):19-24
pubmed: 30446776
Cytokine. 1998 Apr;10(4):307-12
pubmed: 9617577
Sci Rep. 2017 Aug 1;7(1):7086
pubmed: 28765524
Chronobiol Int. 2011 Apr;28(3):267-74
pubmed: 21452922
J Clin Pharmacol. 2013 Mar;53(3):326-33
pubmed: 23444285
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):582-7
pubmed: 22184247
Front Cell Dev Biol. 2021 Dec 08;9:788680
pubmed: 34957116
Biochem Pharmacol. 2019 Jul;165:152-169
pubmed: 30910693
RMD Open. 2016 Mar 18;2(1):e000203
pubmed: 27042335
J Cell Sci. 2020 Jul 1;133(13):
pubmed: 32611680
Stem Cell Reports. 2018 Jan 9;10(1):180-195
pubmed: 29276151
PLoS One. 2010 Jul 12;5(7):e11527
pubmed: 20634945
Nat Rev Dis Primers. 2018 Feb 08;4:18001
pubmed: 29417936
Cell Rep. 2018 Jul 10;24(2):366-378
pubmed: 29996098
J Neuroendocrinol. 2003 Apr;15(4):432-7
pubmed: 12622846
Front Immunol. 2018 Jun 26;9:1467
pubmed: 29997624
J Pharm Pharmacol. 2009 Oct;61(10):1333-8
pubmed: 19814865
Bone. 2016 Mar;84:194-203
pubmed: 26789548
J Biol Chem. 2014 Jun 6;289(23):16374-88
pubmed: 24770415
Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi28-36
pubmed: 23221584
J Bone Miner Res. 2017 Apr;32(4):872-881
pubmed: 27925286
Front Immunol. 2021 Nov 09;12:700431
pubmed: 34858390
Nat Immunol. 2016 Jan;17(1):26-33
pubmed: 26681459
Int J Mol Sci. 2021 Mar 08;22(5):
pubmed: 33800290
Front Cell Infect Microbiol. 2022 Feb 23;12:826738
pubmed: 35281442
J Pharmacol Sci. 2011;116(3):264-73
pubmed: 21691040
Ann Intern Med. 2019 Jan 1;170(1):ITC1-ITC16
pubmed: 30596879
Cell. 2005 Sep 9;122(5):803-15
pubmed: 16143109
Cell Signal. 2021 Apr;80:109904
pubmed: 33370580
Int Immunopharmacol. 2020 Jul;84:106549
pubmed: 32416449
Cell Prolif. 2018 Oct;51(5):e12470
pubmed: 30117209
Infect Immun. 2006 Aug;74(8):4750-6
pubmed: 16861663
Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21407-12
pubmed: 19955445
Rheumatology (Oxford). 2013 Aug;52(8):1435-7
pubmed: 23584366
Int J Mol Sci. 2022 Mar 06;23(5):
pubmed: 35270012
Ann Rheum Dis. 2016 Jun;75(6):1187-95
pubmed: 26025971
N Engl J Med. 2023 Feb 9;388(6):529-542
pubmed: 36780677
Ann Rheum Dis. 2013 Feb;72(2):204-10
pubmed: 22562974
Proc Soc Exp Biol Med. 1960 Jan;103:142-4
pubmed: 14398944
Ann Rheum Dis. 2009 Jan;68(1):63-8
pubmed: 18375536
J Bone Miner Res. 2017 Apr;32(4):861-871
pubmed: 27883226
Nature. 1999 Jul 8;400(6740):169-73
pubmed: 10408444
Arthritis Res Ther. 2013 Feb 21;15(1):205
pubmed: 23427807
J Immunol. 2014 Jan 1;192(1):407-17
pubmed: 24307731
Science. 2021 Feb 12;371(6530):
pubmed: 33574181
Life Sci. 2020 Jul 15;253:117636
pubmed: 32251631
Science. 2016 Nov 4;354(6312):572-577
pubmed: 27811267
Lancet. 2008 Jan 19;371(9608):205-14
pubmed: 18207016
J Pharmacol Sci. 2012;120(2):112-20
pubmed: 23018897
J Bone Miner Res. 2016 Jul;31(7):1344-55
pubmed: 26841172
Bone. 2014 Apr;61:1-9
pubmed: 24389417
Rheumatol Int. 2013 Jun;33(6):1447-54
pubmed: 23179262
Joint Bone Spine. 2019 May;86(3):327-333
pubmed: 30227223
Elife. 2020 May 12;9:
pubmed: 32396064